Skip to content
Screener

Regeneron Pharmaceuticals REGN EBITDA

EBITDA at other companies

Merck & Co. logo
Merck & Co.MRK
-$2.95B-146%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$38.9M+11.8%
Glaukos logo
GlaukosGKOS
-$8.4M+40.5%
EyePoint, Inc. logo
EyePoint, Inc. EYPT
-$86.59M-79.1%
Precigen logo
PrecigenPGEN
-$4.9M+77.7%
Amgen logo
AmgenAMGN
——

Other financials

Income statement

See full
Revenue$4.3B+16.7%
Operating income$1.3B+19.8%
Net income$1.3B-6.8%
EPS (diluted)$12.23-4.5%

Balance sheet

See full
Cash & equivalents$2.5B+22.3%
Total debt$2.7B+0.1%
Total equity$31.7B+5.9%
Total assets$41.7B+9.2%

Cash flow

See full
Operating cash flow$813.0M-29.0%
CapEx$240.2M+9.7%
Free cash flow$572.8M-38.1%

Valuation

See full
Market cap$78.52B+29.6%
Enterprise value$78.76B+28.6%
P/E18.1×+4.6×
P/S5.1×+0.8×

Profitability

See full
Gross margin94.9%—
Operating margin24.7%-2.3pp
Net margin27.9%-3.5pp
FCF margin24.2%-2.9pp

Returns & leverage

See full
Return on equity14%-1.3pp
Debt / equity0.1×0.0×
Current ratio3.3×-1.3×

Where this comes from

Calculated from Regeneron Pharmaceuticals’s reported figures.

$1.3Bebit+
$123.7MDepreciation Depletion & Amortization
=$1.42B

The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →

Filed
Jul 30, 2026, 6:52 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000872589-26-000025

FAQ

What is Regeneron Pharmaceuticals's EBITDA?
Regeneron Pharmaceuticals (REGN) reported EBITDA of $1.42B in Q2 2026.
How has Regeneron Pharmaceuticals's EBITDA changed year-over-year?
Regeneron Pharmaceuticals's EBITDA increased by 16.7% year-over-year, from $1.21B to $1.42B.
What is the long-term trend for Regeneron Pharmaceuticals's EBITDA?
Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's EBITDA has grown at a -18.3% compound annual growth rate (CAGR), from $9.23B to $4.12B.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Regeneron Pharmaceuticals's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude